Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Licenses RNAi Tech to Circuit for Pain Therapy

Premium

NEW YORK (GenomeWeb) – Benitec Biopharma this week announced that it has licensed its expressed RNAi technology to Circuit Therapeutics for the development of an intractable pain treatment.

The agreement specifically allows Circuit to use Benitec's technology to silence sodium channel v1.7 (Nav1.7, a voltage-gated sodium ion channel that is expressed at the ends of pain-sensing nerves called nociceptors. A number of local anesthetics work by blocking sodium channels.

"A major focus for Circuit has been the development of novel, gene-based therapies to treat intractable pain," Circuit Chairman Fred Moll said in a statement. "Accessing Benitec's [expressed RNAi] approach, we believe will enable the advancement of our programs."

Specific details of the arrangement were not disclosed, but Benitec said it is "broadly in line with previous license agreements and are within expected guidelines for biotech initiatives in the early stage of development."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.